Physician

Rebecca Amy Kosloff, MD

According to 2025 Medicare claims, Rebecca Kosloff, MD (NPI: 1376500769) practices hematology/oncology in the Naples-Marco Island, FL market, with the plurality of this provider's patient population coming from Collier, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 34135-4773.

Kosloff's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,482 traditional Medicare patients, billed 430,438 HCPCS/CPT codes, and received $5,706,236 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,626 prescription claims across 355 beneficiaries totaling $7,086,474 in drug costs, led by Revlimid (Lenalidomide). DME data shows 13 claims. Open Payments data shows 64 records totaling $1,411. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $2,941,527 to $7,086,474. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $19,789 to $6,033.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,150	500,306	$5,090,634
2016	1,923	559,260	$6,048,925
2017	2,345	552,484	$7,356,186
2018	2,248	561,237	$7,616,365
2019	2,140	645,669	$7,750,497
2020	1,979	563,018	$7,657,531
2021	1,942	499,542	$7,430,872
2022	1,744	452,120	$6,200,823
2023	1,863	439,873	$5,574,972
2024	1,482	430,438	$5,706,236

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	358	2,438	$2,941,527
2016	339	2,381	$4,127,684
2017	365	2,325	$4,259,161
2018	435	2,719	$5,563,346
2019	440	2,439	$6,337,350
2020	425	2,495	$6,691,459
2021	397	2,101	$6,835,382
2022	383	2,000	$8,618,912
2023	392	1,828	$7,456,344
2024	355	1,626	$7,086,474

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	65	497	$94,474
2016	47	361	$48,440
2017	27	163	$37,832
2018	54	236	$30,404
2019	41	149	$13,688
2020	N/R	55	$3,934
2021	N/R	55	$2,661
2022	N/R	N/R	N/R
2023	N/R	35	$5,273
2024	12	13	$2,345

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	750	1,801	$99
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	728	1,485	$13
96372	Injection of drug or substance under skin or into muscle	309	1,034	$11
36415	Insertion of needle into vein for collection of blood sample	1,107	3,256	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	1,115	3,503	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	120	3,360	$2,126,828
Pomalyst	Pomalidomide	35	938	$725,640
Imbruvica	Ibrutinib	39	1,108	$571,449
Ibrance	Palbociclib	37	1,036	$534,940
Calquence	Acalabrutinib Maleate	24	720	$344,998

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	12	13	$2,345

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	64	$1,411	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rebecca Amy Kosloff, MD?

Tedicare shows public-source Medicare data for Rebecca Amy Kosloff, MD (NPI 1376500769), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rebecca Amy Kosloff, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Rebecca Amy Kosloff, MD?

Rebecca Amy Kosloff, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Rebecca Amy Kosloff, MD have Open Payments data?

Rebecca Amy Kosloff, MD has 64 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.